Genentech Builds Case For Rituxan In Pemphigus With Comparator Study Data
Genentech reports that Rituxan yields better results over 52 weeks in pemphigus patients than off-label use of CellCept. Principia, meanwhile, unveils positive Phase II data for its pemphigus candidate.
You may also be interested in...
Public Company Edition: Phathom went public in the US within proposed pricing terms, but Cabaletta’s IPO went to market below a proposed range, while TFF launched in line with earlier plans. Also, Principia’s FOPO raises $210m and Trillium restructures.
First-in-class drug for rare disease EPP obtains FDA approval, company plans treatment center-based rollout. Scenesse, on the market in Europe since 2016, has faced reimbursement hurdles.
Roche presented a strong first-half performance and raised its outlook again for the full year as sales continued to be driven by its portfolio of new medicines. It said its delayed takeover of Spark Therapeutics should happen by year-end.